Source: International Congress 2019 – Evaluation of basic science in airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Wu (Chengdu, China), J. Qin (Chengdu, China), Y. Shen (Chengdu, China), H. Wang (Chengdu, China), F. Wen (Chengdu, China). Serum endostatin is a novel marker for COPD associated to lung function decline and exacerbation. 1717

Member's Comments

No comment yet.

Related content which might interest you: Association of elevated CRP and IL-6 with rapid decline in lung function and exacerbation in tuberculosis destroyed lung Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers Year: 2017 Increased serum endotoxin levels as biomarker in acute exacerbations of COPD. Source: International Congress 2018 – Biomarkers of COPD Year: 2018 Increased serum α1-antitrypsin level in COPD patients with predominant lung emphysema Source: Eur Respir J 2001; 18: Suppl. 33, 248s Year: 2001 Leptin levels are associated with reduced lung function in men with COPD Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021 Plasma markers of oxidative protein damage do not correlate with lung function or COPD in smokers Source: Eur Respir J 2006; 28: Suppl. 50, 144s Year: 2006 Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017 Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009 Elevated circulating MMP-9 is associated with increased exacerbation risk in COPD: results from SPIROMICS and COPDGene Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Leptin receptor polymorphisms and lung function decline in COPD Source: Eur Respir J 2009; 34: 103-110 Year: 2009 Plasma biomarkers and response to therapy at exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 39s Year: 2007 Serum hyaluronidase-1 is increased in COPD exacerbations and is associated with COPD severity and outcomes Source: International Congress 2018 – Disease exacerbations from a molecular point of view Year: 2018 Prevalence of alpha1-antitrypsin deficiency and its influence on lung function decline in patients with severe asthma Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Serum interleukin-6 levels correlate with malnutrition in patients with acute exacerbation of COPD Source: Annual Congress 2009 - Organisation of care for individuals with chronic respiratory disease Year: 2009 Effect of one moderate or mild exacerbation on lung function and serum inflammatory markers in ex smokers patients with COPD Source: Annual Congress 2009 - Cellular-tissue modifications and functional evaluation in COPD patients Year: 2009 Serum periostin is not a good biomarker to identify Th2-driven inflammation in COPD Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Serum angiopoietin-2 levels in stable and exacerbated chronic obstructive pulmonary disease Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema Year: 2015 A novel serum biomarker of type XXVIII collagen turnover is elevated in lung cancer but not in COPD Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005 Serum hyaluronate: A new biomarker of passive smoking-induced lung injury in asthmatic patients Source: Annual Congress 2010 - Innovations in the assessment of airway diseases Year: 2010